Research on prostate cancer biology, detection, and outcomes. Covers genetic clues, DNA damage, diet and survival, and screening awareness.
A large Mayo Clinic cohort study found that statin use is associated with a reduced risk of prostate cancer, with non-statin users three times more likely to develop the condition. Statins may also protect against erectile dysfunction, particularly among older men, and prevent prostate enlargement.
MRI technology successfully identifies prostate cancer spread beyond the gland, helping doctors determine if surgery is necessary. The study reviewed 119 patients and found that MRI correctly identified 95% of T2 cases and 75% of T3 disease
Researchers developed a smart bomb-like drug delivery system that combines imaging with chemotherapy for prostate cancer treatment, showing promise in reducing tumor cells.
A study of 1,495 veterans found that those exposed to Agent Orange had a nearly 50% increased risk of prostate cancer recurrence and more aggressive cancers. This highlights the need for closer monitoring and timely intervention in these patients.
A University of Leicester team is developing a combined diagnosis/therapeutic strategy for prostate cancer using cutting-edge magnetic nanoparticles. The technology aims to identify and treat cancer cells at an early stage, reducing the need for surgical removal.
Researchers found racial disparities in cancer survival rates disappear when analyzing smaller geographic areas like neighborhoods. The study suggests that modifiable factors such as socioeconomic differences and access to medical care contribute to these disparities.
A novel gene fusion, SLC45A3-ELK4, is highly expressed in prostate cancers and detectable in urine. This biomarker may help distinguish clinically significant from indolent disease.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Researchers have developed a novel compound, MDV3100, which blocks the androgen receptor in CRPC cells, lowering PSA levels and reducing tumor growth.
Researchers have developed two new drugs, RD162 and MDV3100, that prevent male hormones from stimulating growth of prostate cancer cells. These compounds appear to work well even in prostate cells with heightened sensitivity to hormones, which makes them effective against drug-resistant prostate cancer.
A study identifies RNF6 as a protein that modifies androgen receptor activity in hormone-refractory prostate cancer. Inhibition of RNF6 shows promise as a new strategy for treating advanced prostate cancer, which no longer responds to traditional therapies.
Research shows that surgeons operating on prostate cancer patients face a steep learning curve when switching to laparoscopic surgery. Patients may be at increased risk of cancer recurrence if treated by inexperienced surgeons. To minimize this risk, specialist cancer centers with experienced surgeons are recommended.
Researchers at the University of Tokyo identified a novel biomarker to monitor acute kidney injury, while a study found that the unfolded protein response contributes to nerve cell death in Alzheimer's Disease. Additionally, a bacterial toxin disrupts intestinal epithelial barrier function, leading to systemic infection.
Researchers have found that sarcosine distinguishes between slow-growing and aggressive prostate cancers. The metabolomic analysis suggests that sarcosine is highly associated with tumour development and can predict the aggressiveness of tumors.
Human cytomegalovirus (HCMV) induces telomerase expression in both normal and malignant human cells, stimulating cell proliferation and immortalization. Additionally, a dietary supplement containing selenium, vitamin E, and beta-carotene reduces gastric cancer and overall mortality in individuals taking the supplements.
The SPCG-4 trial found that radical prostatectomy significantly reduces prostate cancer mortality and risk of metastases, with little to no increase in benefits over a 12-year follow-up. The study suggests that well-structured pre-treatment information, patient understanding, and support are crucial for managing prostate cancer.
Researchers are developing new classes of anti-androgen therapies, including MDV3100, abiraterone, and OGX-427, to treat castrate-resistant prostate cancer (CRPC). Angiogenesis inhibitors like bevacizumab target vascular endothelial growth factor (VEGF) to slow tumor growth and metastasis.
A major US study of 75,000 men found that annual prostate cancer screening led to more diagnoses but not fewer deaths. The study suggests that men with a short life expectancy may not need screening, and further research is needed to determine its benefits and harms.
The study found that PSA screening can reduce prostate cancer deaths by 20%, saving one life for every 1,408 men screened. The European Association of Urology's largest prostate cancer screening study provides robust evidence for the effectiveness of screening on prostate cancer mortality.
Researchers at the University of Nebraska Medical Center discovered that certain estrogen metabolites can damage DNA, initiating breast and prostate cancer. A new dietary supplement called Preventium combines natural compounds to block this mechanism, potentially reducing cancer risk.
A multi-center study recommends that men diagnosed with low-risk prostate cancer can safely choose observation over immediate treatment, closely monitored. This approach is associated with a low risk of metastatic spread and is not a total disregard for patients with prostate cancer.
Researchers found that study methods and definitions of lead time significantly impact estimates of prostate cancer screening's effectiveness. The study suggests a need for clear methodology to accurately interpret findings.
Daily folic acid supplements may increase prostate cancer risk by more than twice that of placebo. Baseline dietary folate intake and plasma levels showed a trend towards reduced risk but did not reach statistical significance. Researchers suggest large epidemiological studies using improved methods to study diet and cancer prevention.
A daily folic acid supplement increased prostate cancer risk by more than two-fold compared to placebo, according to a USC-led study. The findings contradict previous observations suggesting folate might lower prostate cancer risk.
Researchers at the University of Michigan have identified a potential new biomarker, sarcosine, that can distinguish between aggressive and non-aggressive prostate cancers. Sarcosine levels in urine may help predict cancer aggressiveness and identify patients who need aggressive treatment.
Focal cryoablation, a minimally invasive treatment, is as effective as surgery in destroying diseased tumors and can be considered a first-line treatment for patients of all risk levels. The use of 3-D transperineal mapping biopsy heavily impacted how patients' disease was managed in 70 percent of cases.
A new intervention being tested at Case Western Reserve University aims to improve the lives of men with incontinence problems from prostate cancer treatments. The 'Stay Dry' program combines pelvic floor muscle exercises with biofeedback techniques and therapy, and will be compared to standard care in a four-year study.
Researchers at UIC will enroll 500 men with early-stage prostate cancer to investigate the biological factors behind poorer outcomes in obese patients. The study aims to identify new approaches to preventing prostate cancer recurrence or progression after treatment.
Researchers used a six-gene model to stratify patients with castration-resistant prostate cancer, predicting survival and accuracy rates. The study found the model accurate in predicting low-risk patients' survival and high-risk patients' mortality.
The Society of Interventional Radiology will present research on treatments for kidney, prostate, bone cancer, herniated disks, and more at its 34th Annual Scientific Meeting. The meeting will showcase innovative interventional radiology studies and treatments.
Researchers identified proepithelin as a protein that encourages cell growth and migration in prostate cancer cells, especially androgen-independent ones. Proepithelin overexpression may serve as a clinical marker for prostate cancer diagnosis and a therapeutic target.
The new guideline encourages healthy men to talk to their doctors about using 5-alpha reductase inhibitors (5-ARIs) to prevent prostate cancer, with a 25% relative risk reduction in most men. ASCO developed a Decision Aid Tool to help patients and families understand the risks and benefits of 5-ARIs.
Researchers found that PSA levels are more predictive of three-year prostate cancer risk in African-American men compared to Caucasian men with a family history. The study's findings suggest that PSA levels may be used to identify high-risk patients for earlier screening.
Research suggests that discontinuing routine PSA screening in elderly men (75+ years old) with low PSA levels may not increase undetected lethal disease rates. Instead, it could avoid unnecessary treatments and reduce diagnostic costs. Men over 75 with PSA < 3ng/ml have a low risk of developing high-risk prostate cancer.
A Johns Hopkins study found that older men with PSA levels less than 3 nanograms per milliliter are unlikely to die of or experience aggressive prostate cancer. This suggests that routine PSA testing may be unnecessary for some older men, potentially reducing costs and morbidity.
Researchers have identified a new biomarker for fatal prostate cancer, which is high levels of ionized serum calcium. Men with the highest levels of ionized serum calcium are three times more likely to die of prostate cancer than those with lower levels.
Researchers found that combining DHEA with red clover isoflavones increased testosterone production and reversed androgenic effects in prostate cells. The study suggests a potential cancer prevention effect of herbal supplements like DHEA, warranting further research.
A panel of small molecules, including sarcosine, has been identified as potential markers for aggressive prostate cancer. Sarcosine was found in higher levels in advanced prostate cancer samples and was a better indicator than traditional PSA test.
Researchers have identified a new biological marker, sarcosine, that indicates prostate cancer progression and spreading. Sarcosine levels increase in tumor cells and urine samples as the disease develops.
A new method uses circulating tumour cells to monitor disease status and predict survival in patients with advanced prostate cancer. Changes in CTC number before and after treatment are strongly associated with risk, making it a more predictive biomarker than PSA.
Researchers at Burnet Institute develop a potential new treatment for prostate cancer using a monoclonal antibody targeting the PIM-1 molecule, which plays a critical role in cell survival and proliferation. Laboratory models show significant inhibition of cancer cell growth, paving the way for clinical trials.
Research from Albert Einstein College of Medicine found that Ashkenazi Jewish men carrying specific gene mutations have a higher risk of developing aggressive prostate cancer. The study identified three particular mutations, including BRCA1-185delAG and the mutated BRCA2 gene, which increased the risk of high-grade tumors.
A study of over 800 men found that those who were very sexually active in their twenties and thirties were more likely to develop prostate cancer, especially if they masturbated frequently. However, the risks diminished with age, particularly in a man's fifties.
Researchers investigate thalidomide for biochemical recurrence and adjuvant radiotherapy for improved survival, reducing metastases risk by 29%. Both treatment options show promise for patients with biochemically recurrent prostate cancer after surgery.
Researchers have found that certain measles virus vaccine strain derivatives can effectively infect, replicate in and kill prostate cancer cells. This type of treatment, called virotherapy, shows promise as a potential cure for locally advanced or metastatic prostate cancer.
Researchers have discovered a key difference in hormone receptors on prostate cancer cells in patients who no longer respond to hormone deprivation therapy. The finding, published in Cancer Research, could lead to new targets for treating prostate cancer and monitoring disease progression.
A recent study by Charles Drew University found that gay and bisexual black men have the lowest use of prostate cancer testing. The percentage of gay and bisexual black men who received the PSA test was 12-28% lower than heterosexual blacks and 15-28% lower than gay and bisexual whites.
Researchers discovered that noscapine, an ingredient in common cough medication, reduced tumor growth by 60% and limited tumor spread by 65% without causing side effects. The findings suggest a promising treatment for advanced prostate cancer.
A UCLA study found that low-income men are more likely to present with advanced prostate cancers, highlighting the need for increased access to screening services. The study also revealed that diagnosis rates for lower-risk cancers did not increase over time among IMPACT patients, unlike in more affluent populations.
A recent study published in The Journal of Urology found that low-income men are diagnosed with more advanced prostate cancer due to inadequate access to screening services. This disparity is significant, as the study reveals that 19% of these men were diagnosed with metastatic cancer, compared to 4% in the general population.
In a phase III trial, combining endocrine treatment with radiotherapy reduced prostate cancer mortality by half compared to endocrine treatment alone. The study found significant superiority of the combined treatment over hormone therapy alone in reducing prostate cancer-specific mortality and overall survival.
The study found that the majority of men complied with PSA and DRE tests, with over 84% of diagnosed cancers picked up by screening. Cancer detected at baseline tended to be more serious and aggressive than those detected later.
A recent study led by Massachusetts General Hospital researchers found that hormone therapy for prostate cancer does not appear to increase the risk of death from cardiovascular disease. However, other adverse effects such as diabetes and heart disease still exist, necessitating careful treatment strategies.
A major study of over 14,000 male physicians found that long-term vitamin E and C supplementation had no significant impact on prostate cancer or total cancer risk. The study suggests that these supplements may not be effective in preventing cancer in middle-aged and older men.
A large cancer prevention trial found no association between supplementation with vitamin E or selenium and a reduced risk of prostate cancer. The study included 35,533 men and followed them for up to 7 years, concluding that these supplements were ineffective in preventing prostate cancer.
Researchers from Baylor College of Medicine found that prostate cancer promotes the growth of new nerves and axons, a phenomenon associated with more aggressive tumors. This discovery could lead to new targets for treatment, as neurogenesis is present in more aggressive cancers.
Researchers at USC have discovered a novel approach to suppressing prostate cancer development by inactivating a specific protein biomarker. By blocking the glucose-regulated protein GRP78, they found that prostate tumor progression can be halted in animal models.
African-American men and those with a family history of prostate cancer are at higher risk due to genetic factors. Genetic markers associated with increased risk have been found to be more prevalent in these populations, suggesting they may be used for personalized screening recommendations.
Researchers found that men taking aspirin had significantly lower PSA levels, especially among those with prostate cancer. However, this may affect the ability to detect early-stage prostate cancer through PSA screening.
A new cross-Canada study found that breast and prostate cancer treatment can cause significant bone loss, affecting up to 46,000 people each year. The researchers discovered that medications called bisphosphonates can help combat osteoporosis and fractures in cancer patients.
A recent study found that statin use is associated with a decline in prostate-specific antigen (PSA) levels, suggesting potential benefits for prostate cancer screening and management. The study, which analyzed data from over 1,200 men, showed a median decline of 4.1% in PSA levels after starting statin therapy.